Calibr-Skaggs doses first patient with switchable CAR-T cell therapy in a phase 1 trial for metastatic breast cancer CLBR001 ABBV-461 is a novel, investigational, two-part, switchable chimeric antigen T cell (sCAR-T) immunotherapy designed to treat solid tumors.
June 17, 2025
LA JOLLA, CA The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options. This is the first study of the sCAR-T platform in solid tumors.
CAR-T therapy has been transformative for patients with hematological malignancies who failed numerous prior treatments. However, conventional CAR-T therapies have not yet been as successful at treating patients with solid tumors. This challenge is what Calibr-Skaggs' switchable CAR-T cell therapy platform was designed to address.
The sCAR-T platform developed by Calibr-Skaggs is designed to enhance the precision and safety of CAR-T therapies, and has demonstrated promising preliminary results in a phase 1 clinical trial for hematological malignancies. Additionally, initial results have demonstrated CLBR001 sCAR-T cells can expand in the body in significantly greater numbers than conventional CAR-T cells, affording a better chance of penetrating the hostile solid tumor microenvironment. And the switch offers an added advantage by allowing the cells to rest, potentially avoiding CAR-T exhaustion.
There's a critical need to develop gene and cell therapy approaches that are able to recreate the success observed in blood cancers for patients with solid tumors like breast cancer, said Travis Young, PhD, vice president of biology at Calibr-Skaggs. By integrating an antibody-based switch,' there's the potential to enhance the precision of targeting solid tumor cells, while also mitigating potential safety risks.
The clinical trial testing CLBR001 ABBV-461 is now underway in the US. CLBR001 ABBV-461 is being developed in collaboration with AbbVie.
About the Phase 1 Clinical Trial
NCT06878248 is a Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Combination of CLBR001, an Engineered Autologous T Cell Product, and ABBV-461, an Antibody-Based Biologic, in Subjects with Locally Advanced or Metastatic Breast Cancer. The goals are to establish the safety and efficacy of the two-part therapy while establishing optimal biologic switch doses. Patients will be administered a single infusion of CLBR001 cells post lymphodepletion followed by cycles of ABBV-461 switch with regular assessments of safety and disease response to treatment.
About Calibr-Skaggs' sCAR-T Platform
This platform uses a unique two-component system: an engineered T cell product (CLBR001) and an antibody-based drug the switch.' The switch binds to both the target antigen on tumor cells and the CLBR001 cells, effectively switching on the CLBR001 cells to eliminate the cancerous cells, which is like a remote control for physicians. This design feature provides potential efficacy advantages and also safety optionality, as the physician can pause dosing of the switch in the case of an adverse event.
About Scripps Research
Scripps Research is an independent, nonprofit biomedical research institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at www.scripps.edu.
About the Calibr-Skaggs Institute for Innovative Medicines
The Calibr-Skaggs Institute for Innovative Medicines was founded on the principle that the creation of new medicines can be accelerated by pairing world-class biomedical research with state-of-the-art drug discovery and development capabilities. Leveraging the unique scientific framework of Scripps Research, Calibr-Skaggs has created a portfolio of drug candidates based on Scripps Research technologies and is shaping a new paradigm for advancing nonprofit biomedical research to impact patients. Learn more at calibr.scripps.edu.
*For inquiries, please contact Alex Brooks, abrooks@scripps.edu.
Cancer Calibr-Skaggs
Most recent headlines
06/10/2025
France T l visions, France's leading broadcaster, has received the 2025 EBU ...
04/09/2025
Monumental Sports & Entertainment (MSE), in collaboration with Dalet, has been a...
07/08/2025
July 8 2025, 22:30 (PDT) Tata Motors & Dolby Bring Dolby Atmos to Harrier.ev, R...
12/07/2025
As the death toll continues to mount, with at least 120 killed and more than 170 people still missing on July 10 from devastating Texas floods, a number of broa...
12/07/2025
EL SEGUNDO, Calif., and MIAMI -DirecTV and TelevisaUnivision have signed a deal that will make the ad-supported premium subscription tier of ViX, ViX Premium wi...
11/07/2025
PARK CITY, UTAH, July 11, 2025 - The nonprofit Sundance Institute announced today the 11 producers chosen for its annual Producers Labs, returning to Ucross Fou...
11/07/2025
If you've ever wondered what might be playing in Clark Kent's headphones...
11/07/2025
L3Harris Technologies President of Intelligence, Surveillance and Reconnaissance Jason Lambert and General Manager of L3Harris Waco facility Sean Ling held a ce...
11/07/2025
ARLINGTON, Va. WETA, the flagship public media station in the national capital area, has launched WETA+, a new streaming service tailored for the local Washingt...
11/07/2025
The Federal Communications Commission has emerged as one of the central players in the broadcast TV landscape in 2025, with its deregulatory policies sparking h...
11/07/2025
Calrec will introduce usability, customization and system enhancements across its entire range of Argo consoles during IBC2025, Sept. 12-15, at the RAI Amsterda...
11/07/2025
LONDON Encompass Digital Media said it will support live and on-demand viewing of the 2025 FIFA Club World Cup across multiple global regions for sports enterta...
11/07/2025
Two-thirds of broadcast engineers reaped the benefits of a pay raise within the last year....
11/07/2025
CARY, N.C. SmallHD has launched the Quantum 27, a new 26.5-inch Quantum-Dot OLED monitor designed to deliver postproduction image quality in a compact, set-frie...
11/07/2025
The Federal Communications Commission's Enforcement Bureau and Tegna have entered into a consent decree that will settle an investigation into the accidenta...
11/07/2025
WASHINGTON Following news in early July that Paramount had settled President Donald Trump's lawsuit, Sens. Edward J. Markey (D-Mass.) and Ben Ray Luj n (D-N...
11/07/2025
Model/Actriz Performs Lead Single Cinderella on The Late Show with Stephen Colbe...
11/07/2025
Behind the Mic: Amazon Prime Preps for First Season of NBA Action; MSG Networks ...
11/07/2025
SVG New Sponsor Spotlight: Suite Studios' Craig Hering on Adapting to Client...
11/07/2025
2025 SVG Content Management Forum Breaks Down AI's Impact, Continued Transit...
11/07/2025
A Journey HOME: University of Nebraska's HuskerVision Goes IP Leaders from the HuskerVision and Lawo share their IP learnings By SVG Staff
Friday, July 1...
11/07/2025
CMSI, Remote Picture Labs, Ace ESPN's Cloud-Based Editing Efforts for Wimble...
11/07/2025
Netflix Enters the Live-Boxing-Production Ring for Round 2 With Historic Taylor-...
11/07/2025
Back to All News
Too Hot to Handle: Italy Is Coming on July 18 Only on Netflix
Entertainment
11 July 2025
GlobalItaly
Link copied to clipboard
July 11, 20...
11/07/2025
Back to All News
Netflix Will Release Death Inc. Seasons 1, 2 and 3
Entertainment
11 July 2025
GlobalSpain
Link copied to clipboard
Season 1
Season 2
Se...
11/07/2025
AI and Multimedia Authenticity Standards Collaboration launches two papers to guide the future of AI integration, today at the AI for Good Global Summit
The...
11/07/2025
Ceramics - the humble mix of earth, fire and artistry - have been part of a global conversation for millennia.
From Tang Dynasty trade routes to Renaissance pa...
10/07/2025
The current holder of the prestigious Thomson Foundation Young Journalist of the Year Award has been forced to stop reporting over fears for her safety in Afgha...
10/07/2025
Spotify is turning up the volume on Australian music with a multipronged initiative designed to highlight the dominance of Australian artists on the global stag...
10/07/2025
This is not a drill: Oasis is back on the road-marking its first live performanc...
10/07/2025
The music industry depends on fresh ideas, bold voices, and emerging talent. Yet across the U.K., too many young musicians lack the space to develop their craft...
10/07/2025
NEW YORK - July 10, 2025 - Nielsen, the global leader in audience measurement, data and analytics, today announced that it appointed Richard Pacheco as head of ...
10/07/2025
Local newscasts don't exist in a vacuum. News directors and station management constantly evaluate what's working, what isn't and perhaps most impor...
10/07/2025
Lawo has announced that Stuttgart Media University (Hochschule der Medien, HdM) has comprehensively modernized its central recording studio after selecting an I...
10/07/2025
The Society of Motion Picture and Television Engineers (SMPTE) has opened early-bird registration for the Media Technology Summit, which will take place in a ne...
10/07/2025
NASHVILLE, Tenn. TNDV Television has launched Aspiration 35, a new version of its 40-foot Aspiration truck reimagined for cinematic multicamera productions....
10/07/2025
BURBANK, Calif. Key Code Education, a provider of instructor-led postproduction training, is growing its curriculum with new programs for beginner and intermedi...
10/07/2025
HACKENSACK, N.J. Actus Digital will demonstrate how broadcasters can transform compliance monitoring from a necessary expense into a strategic revenue driver at...
10/07/2025
The Federal Register has published a summary of the Federal Communications Commission's Public Notice seeking comments on its ownership rules that lists a d...
10/07/2025
Back to All News
Netflix Presents the Official Trailer for SuperestarPlay Video
Play Video
Entertainment
10 July 2025
GlobalSpain
Link copied to clipboard...
10/07/2025
In the race to understand our planet's changing climate, speed and accuracy are everything. But today's most widely used climate simulators often strugg...
10/07/2025
As one of the world's largest emerging markets, Indonesia is making strides toward its Golden 2045 Vision - an initiative tapping digital technologies and...
10/07/2025
10 Jul 2025
VEON and Cohen Circle Secure Investor Commitments for Kyivstar Listing Kyiv, New York, Dubai, and Philadelphia - July 10, 2025 - VEON Ltd. (Nasdaq:...
10/07/2025
5G for all? What the DFL's use of Easy5G and RefCam could mean for events in...
10/07/2025
Save the Date: PGA TOUR Studios Welcomes SVG Remote Production Summit on Oct 14-...
10/07/2025
Cloud on the Road: How Remote-Production-Service Providers Are Adapting to a New...
10/07/2025
Seattle Kraken's Ryan Schaber on the NHL Team Taking Live Game Productions I...
10/07/2025
FOX Sports Reboots Small Control Room in Los Angeles as Hub for Vertical-First P...
10/07/2025
SVG Sit-Down: MSE's Zach Leonsis, ViewLift's Rick Allen Go Deep on Joint...
Calibr-Skaggs doses first patient with switchable CAR-T cell therapy in a phase 1 trial for metastatic breast cancer CLBR001 ABBV-461 is a novel, investigational, two-part, switchable chimeric antigen T cell (sCAR-T) immunotherapy designed to treat solid tumors.
